Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy
NCT ID: NCT05416034
Last Updated: 2022-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2017-12-01
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rehabilitative Effect of the Use of a Gait Exoskeleton in Patients With Neuromuscular Disease or Cerebral Palsy
NCT04813601
Evaluation of the Exoskeleton ATLAS 2030 as Robot-assisted Physical Therapy to Children With Neuromuscular Diseases
NCT04837157
Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy
NCT05551364
Impact of the Atlas 2030 Pediatric Exoskeleton on Gait Functionality and Quality of Life in Children With Cerebral Palsy or Related Conditions
NCT07066956
Safety and Usability of a Robotic Gait Device for Children and Adolescents With Neurological or Neuromuscular Disease in Their Natural Environment
NCT06167954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Use of the ATLAS 2030 exoskeleton at home
Children with Spinal Muscular Atrophy Type II will received robot assisted gait therapy with the ATLAS 2030 exoskeleton at their homes 5 days a week during two months in 60 minutes sessions
Use of the ATLAS 2025 exoskeleton at home
Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Use of the ATLAS 2025 exoskeleton at home
Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a confirmed diagnostic of Spinal Muscular Atrophy Type II
Exclusion Criteria
* Hip-knee distance less than 22 cm or greater than 38cm
* Knee-ankle distance less than 21 cm or greater than 37cm
* Distance between trochanters less than 24 cm or greater than 40cm
* Joint range limit greater than 20º
4 Years
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
OTHER
MarsiBionics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Ramón y Cajal
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KINDER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.